Author:
de Visser Marianne,De Bleecker Jan
Reference9 articles.
1. Inclusion body myositis: Update on the diagnostic and therapeutic landscape;Naddaf;Front Neurol,2022
2. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial;Hanna;Lancet Neurol,2019
3. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial;Machado;Lancet Neurol,2023
4. Targeting protein homeostasis in sporadic inclusion body myositis;Ahmed;Sci Transl Med,2016
5. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis;Britson;Sci Transl Med,2022